Evidence map›Paper›PMID 33745886›Full record

ArticleThe Journal of allergy and clinical immunology2021

Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Jason Gotlib, Tracy I George, Melody C Carter, K Frank Austen, Bruce Bochner, Daniel F Dwyer, Jonathan J Lyons, Matthew J Hamilton, Joseph Butterfield, Patrizia Bonadonna and 19 more

Open access · bronzeAbstract readConference Proceedings
In one paragraph

Article in The Journal of allergy and clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 8 countries.

Jason GotlibDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, Calif. Electronic address: jason.gotlib@stanford.edu.
Tracy I GeorgeDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah.
Melody C CarterLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
K Frank AustenDepartment of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Boston, Mass.
Bruce BochnerDepartment of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Daniel F DwyerDepartment of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Boston, Mass.
Jonathan J LyonsLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Matthew J HamiltonDivision of Gastroenterology, Hepatology and Endoscopy. Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
Joseph ButterfieldMayo Clinic, Division of Allergic Diseases, Rochester, Minn.
Patrizia BonadonnaAllergy Unit, Verona University Hospital, Verona, Italy.
Catherine WeilerMayo Clinic, Division of Allergic Diseases, Rochester, Minn.
Stephen J GalliDepartment of Pathology, Stanford University School of Medicine, Stanford, Calif; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, Calif.
Lawrence B SchwartzDepartment of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Virginia Commonwealth University, Richmond, Va.
Hanneke Oude ElberinkInternal Medicine, Section Allergology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Anne MaitlandDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Theoharis TheoharidesDepartment of Immunology, Tufts University School of Medicine, Boston, Mass.
Celalettin UstunDivision of Hematology, Oncology and Cellular Therapy, Department of Medicine, Rush University, Chicago, Ill.
Hans-Peter HornyInstitute of Pathology, Ludwig-Maximilian-University, Munich, Germany.
Alberto OrfaoServicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC, CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Germany.
Michael DeiningerDivision of Hematology and Hematologic Malignancies, The University of Utah, and Huntsman Cancer Institute, Salt Lake City, Utah.
Deepti RadiaDepartment of Clinical Haematology, Guys and St Thomas' NHS Hospitals, London, United Kingdom.
Mohamad JawharUniversity Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Hanneke Kluin-NelemansDepartment of Haematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Dean D MetcalfeLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Michel ArockLaboratory of Haematology, Pitié-Salpêtrière Hospital, Paris, France.
Wolfgang R SperrDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Peter ValentDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Mariana CastellsBrigham and Women's Hospital, Division of Allergy and Clinical Immunology, Boston, Mass; Harvard Medical School, Boston, Mass.
Cem AkinDivision of Allergy and Immunology, University of Michigan, Ann Arbor, Mich.
Brigham and Women's Hospital · USMayo Clinic · USMedical University of Vienna · ATNational Institutes of Health · USCentro de Investigación del Cáncer · ESHuntsman Cancer Institute · USIcahn School of Medicine at Mount Sinai · USLudwig-Maximilians-Universität München · DENational Institute of Allergy and Infectious Diseases · USNorthwestern University · USRush University · USSorbonne Université · FRStanford Cancer InstituteStanford University · USTufts University · USUniversity Hospital Heidelberg · DEUniversity Medical Center Groningen · NLUniversity of Groningen · NLUniversity of Michigan–Ann Arbor · USUniversity of Utah · US

Funding

The Pathogenesis, Diagnosis, And Treatment Of Systemic Mast Cell DisordersZIAAI000249 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOMAROW, HIRSH D · 2009 to 2025
$16.5M
Translational studies in allergic reactions and inflammationZIAAI001192 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LYONS, JONATHAN · 2014 to 2023
$12.7M
American Initiative in Mast Cell Diseases (AIM)R13TR002722 · NCATS · STANFORD UNIVERSITY · PI AKIN, CEM, GOTLIB, JASON R · 2019 to 2019
$15k
Austrian Science Fund FWF P 32470NCATS NIH HHS R13 TR002722
6 · The paper itself

Abstract

The American Initiative in Mast Cell Diseases (AIM) held its inaugural investigator conference at Stanford University School of Medicine in May 2019. The overarching goal of this meeting was to establish a Pan-American organization of physicians and scientists with multidisciplinary expertise in mast cell disease. To serve this unmet need, AIM envisions a network where basic, translational, and clinical researchers could establish collaborations with both academia and biopharma to support the development of new diagnostic methods, enhanced understanding of the biology of mast cells in human health and disease, and the testing of novel therapies. In these AIM proceedings, we highlight selected topics relevant to mast cell biology and provide updates regarding the recently described hereditary alpha-tryptasemia. In addition, we discuss the evaluation and treatment of mast cell activation (syndromes), allergy and anaphylaxis in mast cell disorders, and the clinical and biologic heterogeneity of the more indolent forms of mastocytosis. Because mast cell disorders are relatively rare, AIM hopes to achieve a coordination of scientific efforts not only in the Americas but also in Europe by collaborating with the well-established European Competence Network on Mastocytosis.

Indexed as

Disease ManagementDisease SusceptibilityHumansMastocytosisResearchTranslational Research, BiomedicalAmerican Initiative in Mast Cell Diseases (AIM)anaphylaxisEuropean Competence Network on Mastocytosis (ECNM)hereditary alpha-tryptasemiamast cell activation syndromesiglec-8Systemic mastocytosis

Identifiers

PMID33745886
PMCPMC9521380
OpenAlexW3134302591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.